Additional discussion of these and other factors affecting the company's business and prospects is contained in the company's periodic filings with the Securities and Exchange Commission.
I will now turn the call over to Dr. Marc Grodman, President and Chief Executive Officer.
Delores, thank you very, very much. This past quarter, we posted strong consistent results in terms of virtually every financial metric possible. I believe it's important to spend some time today to put our performance in perspective. Before that, as usual I would like Sam Singer, our CFO to review our results, and then I would like add some additional comments and color following his comments. Sam?Sam Singer Thank you, Marc. Good morning, everyone. During the third quarter fiscal year 2012, which ended on July 31, Bio-Reference recorded net revenues of $172,302,000, the highest quarterly net revenues recorded by the company, compared to $148,029,000 third quarter of the prior fiscal year, an increase of 16%. Gross profit on revenues for the current quarter was $86,049,000 representing a 50% gross profit margin. In the third quarter of the prior year, gross profit on net revenues were $73,432,000, representing a 50% gross profit margin. Earnings per share or net income after taxes were $0.45 per share in the current quarter, versus $0.36 per share in the prior year quarter. Patient count for the current quarter increased to $1,997,000, from $1,745,000 for the prior year quarter, an increase of 14%. Net revenue per patient for the third quarter just ended was $85.65, compared to $84.20 per patient in the same quarter of the prior fiscal year; an increase of 2%. On July 31, 2012, working capital was $140,211,000, a 30% improvement over the $124,266,000 that we reported on October 31, 2011. Our Days Sales Outstanding on July 31, 2012 were 79 days. Our net revenues were $485, 342,609 for the nine-month period ended July 31, 2012, representing a 19% increase over the net revenues for the same nine-month period in the prior fiscal year. Our gross profit on net revenues for the current nine-month period was $2,336,000, $772,000 or 49%, compared to the prior fiscal year of $105,876,000, or 48%.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV